A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

NCT ID: NCT04669041

Last Updated: 2025-09-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 305 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-08
• Study Completion Date: 2022-06-15

Brief Summary

Primary Objective:

To demonstrate the superiority of the single pill combination (SPC) ezetimibe 10 mg/rosuvastatin 10 mg (E10/R10) compared to rosuvastatin 10 mg (R10), in the reduction of low density lipoprotein cholesterol (LDL-C) after 8 weeks.

Secondary Objectives:

• To evaluate the proportion of patients who attain their LDL-C goal.
• To evaluate the effect of SPC (E10/R10) compared to rosuvastatin 10 mg (R10) in reduction of LDL-C at Week 4.
• To evaluate the effect of SPC (E10/R10) compared to R10 on other lipid parameters at Week 4 and Week 8.
• To evaluate the safety of SPC (E10/R10) and R10.

Detailed Description

Study duration per participants is approximatively 16 weeks.

Conditions

Hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Single pill combination (SPC)

Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks

Group Type: EXPERIMENTAL

Rosuvastatin

Intervention Type: DRUG

Pharmaceutical form:Tablet Route of administration: Oral

SPC ezetimibe/rosuvastatin

Intervention Type: DRUG

Pharmaceutical form:Tablet Route of administration: Oral

Placebo

Intervention Type: DRUG

Pharmaceutical form:Capsule Route of administration: Oral

Rosuvastatin

Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks

Group Type: ACTIVE_COMPARATOR

Rosuvastatin

Intervention Type: DRUG

Pharmaceutical form:Tablet Route of administration: Oral

Rosuvastatin active capsule

Intervention Type: DRUG

Pharmaceutical form:Capsule Route of administration: Oral

Placebo

Intervention Type: DRUG

Pharmaceutical form:Tablet Route of administration: Oral

Interventions

Rosuvastatin

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type: DRUG

SPC ezetimibe/rosuvastatin

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type: DRUG

Rosuvastatin active capsule

Pharmaceutical form:Capsule Route of administration: Oral

Intervention Type: DRUG

Placebo

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type: DRUG

Placebo

Pharmaceutical form:Capsule Route of administration: Oral

Intervention Type: DRUG

Other Intervention Names

Crestor®

Eligibility Criteria

Inclusion Criteria

• Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.
• Patients with primary hypercholesterolemia.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Capable of giving signed informed consent.

Exclusion Criteria

• Homozygous familial hypercholesterolemia (FH) (clinically or previous genotyping).
• Patient who has received LDL-C plasmapheresis treatment within 2 months prior to the screening visit, or has plans to receive it during the study.
• Recently diagnosed (within 3 months prior to the screening visit) myocardial infarction (MI), unstable angina, myocardial revascularization (percutaneous coronary intervention [PCI], coronary artery bypass graft surgery [CABG]), transient ischemic attack (TIA), or stroke, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease.
• Planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during the study.
• Severe hypertension (treated or untreated) with systolic blood pressure (SBP) >160 mm Hg or diastolic blood pressure (DBP) >100 mm Hg at study entry.
• History of severe congestive heart failure (New York Heart Association Class IIIb or IV) within the past 12 months.
• Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins, according to Investigator's medical judgement.
• Uncontrolled (as determined by fasting glucose >180 mg/mL or HbA1c >9%) or newly diagnosed (within 3 months of study entry) diabetes mellitus at the screening visit.
• History of cancer within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
• Conditions/situations such as:

• Patient with a short life expectancy.
• Patient with conditions/concomitant diseases making them non-evaluable for the primary efficacy endpoint, according to Investigator's medical judgement.
• Requirement for concomitant treatment that could bias primary evaluation, according to Investigator's medical judgement.
• Impossibility to meet specific protocol requirements (eg, ability to make study visits).
• Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the study.
• Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.
• Known history of hypersensitivity reaction to statins and/or ezetimibe.
• Current myopathy.
• A history of statin-induced myopathy or rhabdomyolysis.
• Current active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x upper limit of normal (ULN) range at the screening visit.
• All contraindications to the active comparator (rosuvastatin) and background therapies or warning/precaution of use (when appropriate) as displayed in the respective National Product Labeling.
• Patients not previously instructed on a cholesterol-lowering diet prior to the screening visit.
• Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to screening visit.
• Use of hormone replacement therapy or oral contraceptives unless regimen has been stable in the past 6 weeks prior to the screening visit and no plans to change the regimen during the study.
• Concomitant administration of cyclosporine (at screening and randomization visits).
• Human immunodeficiency virus (HIV) patients receiving protease inhibitors (at screening and randomization visits).
• Patient who has taken any active investigational drugs (E10/R10) within 1 month or 5 half-lives prior to screening, whichever is longer.
• Laboratory findings obtained during the screening visit (V1):

• Fasting serum TGs >400 mg/dL.
• Positive serum pregnancy test.
• Serum creatine kinase >3 times ULN.
• Thyroid-stimulating hormone (TSH) < lower limit of normal (LLN) or > ULN.
• Glycated hemoglobin A1c (HbA1c) >9%.
• Estimated glomerular filtration rate <30 mL/min/1.73 m2.
• Alanine aminotransferase or AST >3 x ULN.
• Individuals accommodated in an institution because of regulatory or legal order; prisoners or subjects who are legally institutionalized.
• Any technical/administrative reason (eg, patient homeless) that makes it impossible to enroll/randomize the patient in the study.
• Alcohol abuse according to Investigator's medical judgement.
• Participants are dependent on the Sponsor or Investigator (in conjunction with Section 1.61 of the ICH-GCP Ordinance E6).
• Participants are employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.
• Any specific situation during study implementation/course that may rise ethics considerations.
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Investigational Site Number :1560033

Baotou, , China

Investigational Site Number :1560001

Beijing, , China

Investigational Site Number :1560068

Beijing, , China

Investigational Site Number :1560021

Beijing, , China

Investigational Site Number :1560025

Bengbu, , China

Investigational Site Number :1560045

Changchun, , China

Investigational Site Number :1560067

Changchun, , China

Investigational Site Number :1560052

Changsha, , China

Investigational Site Number :1560041

Chengdu, , China

Investigational Site Number :1560060

Chongqing, , China

Investigational Site Number :1560015

Dalian, , China

Investigational Site Number :1560029

Haikou, , China

Investigational Site Number :1560006

Hohhot, , China

Investigational Site Number :1560007

Hohhot, , China

Investigational Site Number :1560014

Jilin, , China

Investigational Site Number :1560020

Jinan, , China

Investigational Site Number :1560061

Lishui, , China

Investigational Site Number :1560071

Liuzhou, , China

Investigational Site Number :1560066

Nanjing, , China

Investigational Site Number :1560055

Nanning, , China

Investigational Site Number :1560027

Shanghai, , China

Investigational Site Number :1560034

Shenyang, , China

Investigational Site Number :1560010

Siping, , China

Investigational Site Number :1560002

Tianjin, , China

Investigational Site Number :1560053

Tianjin, , China

Investigational Site Number :1560047

Wuhan, , China

Investigational Site Number :1560009

Wuhan, , China

Investigational Site Number :1560035

Wuhan, , China

Investigational Site Number :1560022

Xi'an, , China

Investigational Site Number :1560070

Xi'an, , China

Investigational Site Number :1560003

Xuzhou, , China

Investigational Site Number :1560065

Yangzhou, , China

Investigational Site Number :1560057

Yanji, , China

Investigational Site Number :1560064

Yinchuan, , China

Investigational Site Number :1560019

Yueyang, , China

Investigational Site Number :1560062

Yuncheng, , China

Investigational Site Number :1560005

Zhanjiang, , China

Investigational Site Number :1560011

Zhenjiang, , China

Investigational Site Number :1560063

Zhuzhou, , China

Investigational Site Number :1560037

Zibo, , China

Countries

China

References

Su Q, Liu Y, Zhang G, Xu L, Wang M, Mei S, Garon G, Wu Y, Lv Q, Ma C. Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial. Adv Ther. 2023 Dec;40(12):5285-5299. doi: 10.1007/s12325-023-02666-z. Epub 2023 Sep 28.

Reference Type: DERIVED

PMID: 37770770 (View on PubMed)

Related Links

https://www.trialsummaries.com/Study/StudyDetails?id=25279&tenant=MT_SNY_9011

LPS16135 Plain Language Results Summary

Other Identifiers

U1111-1227-3920

Identifier Type: OTHER

Identifier Source: secondary_id

LPS16135

Identifier Type: -

Identifier Source: org_study_id